ProMIS Neurosciences Presents Alzheimer’s Advances, PMN 310 Updates, at 2017 AAN Meeting

ProMIS Neurosciences Presents Alzheimer’s Advances, PMN 310 Updates, at 2017 AAN Meeting
Canada's ProMIS Neurosciences today presented the latest results of its Alzheimer’s disease therapeutic program and discussed its lead candidate drug PMN 310 on the final day of the April 22-28 annual meeting of the American Academy of Neurology in Boston. The company's chief development officer, Johanne Kaplan, presented the poster, “Achieving the optimal profile for Alzheimer’s immunotherapy: Rational generation of antibodies specific for toxic Aβ oligomers," which were written by Dr. Steven Plotkin and his team. The presentation's authors predict five distinct targets on toxic pathogenic Aβ oligomers, using the company’s Collective Coordinates platform, which  predicts novel targets known as disease specific epitopes (DSEs). ProMIS also gave an update on its lead product candidate, PMN 310. "Based on our results presented at this year’s AAN annual meeting, we anticipate ProMIS monoclonal antibodies (mAbs) — selectively targeting toxic forms of Amyloid beta (Aβ) — will demonstrate a ‘best in class’ product profile for treatment of AD," the company's president and CEO, Dr. Elliot Goldstein, said in a press release. "Indeed, by virtually no binding to Aβ monomer, ProMIS mAb products shou
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *